Skip to main content

Table 6 Effect of warfarin and antithrombotics on the risk of lower gastrointestinal bleeding

From: Risk of bleeding after hospitalization for a serious coronary event: a retrospective cohort study with nested case-control analyses

 

Cases

(n = 316)

n (%)

Controls

(n = 2000)

n (%)

Odds ratiosa

(95 % CI)

P value

Warfarin

 Non-useb

276 (87.3)

1813 (90.6)

1 (−)

 

 Current use

32 (10.1)

157 (7.8)

1.10 (0.69–1.78)

0.68

   < 1 month

3 (0.9)

8 (0.4)

1.55 (0.38–6.34)

0.54

  1–12 months

15 (4.7)

44 (2.2)

1.78 (0.89–3.55)

0.10

   > 1 year

14 (4.4)

105 (5.3)

0.73 (0.38–1.40)

0.34

 Recent use

2 (0.6)

11 (0.5)

0.91 (0.19–4.42)

0.91

 Past use

6 (1.9)

19 (0.9)

1.31 (0.49–3.46)

0.59

Antithrombotic

 Non-use AP and non-use warfarinb

18 (5.7)

128 (6.4)

1 (−)

 

 Current AP and non-current warfarin

252 (79.7)

1596 (79.8)

1.00 (0.59–1.71)

1.00

 Non-current AP and current warfarin

24 (7.6)

116 (5.8)

1.01 (0.50–2.02)

0.99

 Current AP and current warfarin

8 (2.5)

41 (2.1)

0.89 (0.35–2.30)

0.82

  1. AP antiplatelets
  2. aEstimates adjusted by age, sex, calendar year, time of follow up after serious coronary event, health services utilisation, smoking, proton pump inhibitor, antithrombotic and nonsteroidal anti-inflammatory drug use, type of serious coronary event and prior peptic ulcer disease using a logistic regression model
  3. bReference category